

Prevalence of *H pylori* in obese attending Obesity therapy Unit

Mumtaz K Hana*, Abdulhadi Alrubaie **, Mohanad abdulmahdi Ahmad ***, Faris Abdulkarim ****

ABSTRACT

Background: Obesity is an increasing health problem in developed countries and has grown into a major global epidemic. Recent studies suggested colonization of the stomach by *H pylori* might affect gastric expression of appetite- and satiety-related hormone and patients cured of *H pylori* infection gained weight. Obesity and *Helicobacter pylori* (*H. pylori*) are important because of the problems they lead and their frequency of occurrence.

Objectives: To find out the prevalence of *H. pylori* infection in obese.

Type of the study: A cross-sectional study

Methods: A total of 32 obese female admitted to the study. Body mass indices (BMI) of all subjects were calculated. *H. pylori* positivity were studied.

Results: The age range of the obese was (20-59) and the BMI (was 25-55 kg/m²). 26 obese (81.25%) were *H pylori* positive, and all obese above 45 were *H pylori* positive.

Conclusions: Obesity and *h pylori* are closely associated and the prevalence of *h pylori* increased with obesity. We consider that *H. pylori* infection can be a risk factor for obesity and almost all obese patients above 45 years were

sero positive. However, further studies evaluating more subjects are required. And we need to do national survey about *h pylori* prevalence in our community

Keywords: Obesity; *helicobacter pylori*; BMI

Al-Kindy College Medical Journal 2017: Vol. 13 No.2
Page: 69-71

* FRCS(Glasgow), CABS, DS. Assistant prof of surgery, Dept. of surgery Alkindy college of Medicine. email mumtazalnaser@yahoo.com

** FICMS, FICMS(GIT), hadirubaie@yahoo.com

***General Surgeon Ibn Al-Nafis Cardiovascular hospital Baghdad- email moh65@yahoo.com

**** CABS, Assistant prof of Medicine, Obesity Research and Therapy unit, University of Baghdad

Received 3th Oct 2016, accepted in final 22th June 2017

Corresponding to: Abdulhadi Alrubaie, email: hadirubaie@yahoo.com

Obesity has grown into a major global epidemic. By 2002, nearly 500 million people were overweight worldwide. In the United States (US), with more than two-thirds of Americans now overweight¹. Obesity is linked with higher risk for several serious health conditions, such as hypertension, type 2 diabetes, hypercholesterolemia, coronary heart disease (CHD), stroke, asthma, and arthritis². Obesity in adults is generally defined as a BMI of 30.0 or greater, with BMI of 25.0-29.9 categorized as overweight³. *Helicobacter pylori*, is a gram-negative a spiral-shaped pathogenic bacterium found on the human gastric mucosa, was first isolated by Warren and Marshall⁴. *H. pylori* is a common bacterium affecting about 50 percent of the world's population. This bacterium causes chronic gastritis, peptic ulcer disease and/or gastric malignancies also studies have its involved in pathogenesis of some extra gastrointestinal disorders like Reynaud phenomena and migraine and cardiovascular diseases^{5,6,7}. The relationship between obesity and *H pylori* eradication is controversial. There are data which demonstrate that eradication of *H pylori* significantly increases the incidence of obesity in patients with peptic ulcer disease, since it increases the level of BMI^{8,9}. Obesity is a well-known risk factor for the development of GERD while occurrence of GERD after the eradication of *H. pylori* infection has been reported and this could be explained to the restoration of acid secretion^{10,11,12}. While according to some studies, the risk of *H pylori* infection does not increase in overweight

young Persons¹³. After *H. pylori* cure, plasma ghrelin increased profoundly in asymptomatic subjects. This could lead to increased appetite and weight gain, and contribute to the increasing obesity seen in Western populations where *H. pylori* prevalence is low¹⁴

Methods : 32 randomly selected female obese attended obesity research and therapy unit (Baghdad-Iraq) between May 2014, and July 31, 2015. Men excluded and age above 20 were included,

Laboratory Assessment: Serological assay for *Helicobacter pylori* antibody is a noninvasive method to detect *H. pylori* infection. It has been reported to have sensitivity and specificity in predicting the status of *H. pylori* infection in untreated patients as accurately as invasive tests^{15,16}. A commercially available enzyme-linked immunosorbent assay kit (Acon, USA) with reported sensitivity and specificity of more than 95% was used to investigate the prevalence of *H pylori* infection.

Results: The seroprevalence of *H. pylori* was 81.25% (26/32) for all cases of obesity. distributions of seropositivity of *H pylori* with respect to age and BMI in cases summarized in table 1.

Table 1 Seropositivity of *h. pylori* in respect to age and BMI

Age	20-29	30-39	40-49	50-59
number	7	9	9	7
BMI	38-52 kg/m2	34.7-41	26-55	37-45
H. Pylori positive	2 (28%)	7 (77.7%)	8 (88.8%)	7 (100%)

Discussion : Increasing attention has recently been paid to the role of *H. pylori* in the pathogenesis of nutritional problems and body weight because of its potential effects on gastric leptin homeostasis which is produced by fat cells and also produced by chief cells in the human stomach, and levels are affected by *Helicobacter pylori*-associated gastritis.¹⁷ Multiple studies have shown that *H. pylori*-positive persons produce lower amounts of ghrelin, its eradication is associated with a subsequent increase in ghrelin production.^{18,19} Prevalence of *H. pylori* infection is related to several confounding factors, such as age and socioeconomic status. Acquiring of infection in developing countries seems to be nearly universal.²⁰ In our study we found most *h. pylori* positive cases were above 30 and 100% of obese above 50 years of age were *h. pylori* positive, if we compare the prevalence of *h. pylori* in our study with study done by Nawafal et al at north of Iraq showed about 78% of people above 40 were positive for *H. Pylori*.²¹ In nearby countries its almost identical like Turkey and Iran where the sero positivity are 80.0% and 88.4-93% respectively while in north Africa like Egypt 90.0%, Algeria 43-92% but in developed countries like United States 30.0% , Canada 23.1% and Germany 48.8% . That's mean if we can compare our results with nearby countries its evident that the sero-positivity of obese similar with that of general population.

Obesity is an important public health problem in the United States. Because of its potential effects on gastric leptin homeostasis, *Helicobacter pylori* may play a role in regulating body weight. In large, US population-based study they found that there was no significant relation between *H. pylori* status, *cagA* status, and being overweight.²² The prevalence of *H. pylori* infection in morbidly obese patients is still controversial . Overall, available studies report a lower prevalence of *H. pylori* infection in obese patients than in the general population.²³ Serum leptin, which is primarily synthesized by adipose tissue, regulates food intake and body weight homeostasis. Leptin is now known to be synthesized in the stomach as well and this source may also be involved in the regulation of food intake and satiety). Gastric inflammation, such as that induced by *H. pylori* (alters leptin secretion in the stomach and change in gastric leptin level resulting from *H. pylori*-induced inflammation may influence food intake and body mass index.¹⁷ Nweneka et al stated that circulating ghrelin

concentration is lower in people infected with *H. pylori* compared to those not infected with the bacterium also this study suggested that eradicating *H. pylori* does not have any significant effect on circulating ghrelin.²⁴ weight gain following *H. pylori* eradication has been demonstrated in numerous studies Zuma et al) reported that eradication of *H. pylori* is associated with decreased gastric leptin levels and subsequent weight gain, although serum leptin levels did not change.²⁵ In conclusions our study showed high incidence of *H. pylori* infection in obese patients, but this could be a part of *H. pylori* infection status in general population if we compare the prevalence of *H. pylori* with nearby countries. This study calls for further studies regarding survey of *h. pylori* infection in general population.

References

- 1- Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in US obesity among adults, 1999-2008. *JAMA*. 2010;303(3):235-241 .
- 2- Hammond RA, Levine R. The economic impact of obesity in the United States. *Diabetes Metab Syndr Obes*. 2010;3:285-295.
- 3- Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. *JAMA*. 2006;295(13):1549-1555.
- 4- Warren JR., Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. (Letter). *Lancet* 1983;1:1273-5.
- 5- Parsonnet J. *Helicobacter pylori* and gastric cancer. *Gastroenterol Clin North Am* 1993; 22: 89-104
- 6- Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, Gong Y, et al. Relationship of *Helicobacter pylori* infection to arterial stiffness in Japanese subjects. *Hypertens Res*. 2005;28(4):283-92.
- 7- Rogha M, Dadkhah D, Pourmoghaddas Z, Shirmeshan K, Nikvarz M, Pourmoghaddas M. Association of *Helicobacter pylori* infection with severity of coronary heart disease. *ARYA Atheroscler*. 2012;7:138-141.
- 8- Fujiwara Y, Higuchi K, Arafa UA, Uchida T, Tominaga K, Watanabe T, Arakawa T. Long-term effect of *Helicobacter pylori* eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. *Hepatogastroenterology* 2002; 49: 1298-1302
- 9- Kamada T, Hata J, Kusunoki H, Ito M, Tanaka S, Kawamura Y, Chayama K, Haruma K. Eradication of *Helicobacter pylori* increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. *Dig Liver Dis* 2005; 37: 39-43
- 10- Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing *Helicobacter pylori* infection in patients with duodenal ulcer may

- provoke reflux esophagitis. *Gastroenterology* 1997; 112: 1442-7.
- 11- Locke GR, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. *Am J Med* 1999; 106:642-912
 - 12- Koike T, Ohara S, Sekine H, et al. Increased gastric acid secretion after *Helicobacter pylori* eradication may be a factor for developing reflux oesophagitis. *Aliment Pharmacol Ther* 2001; 15: 813-20.
 - 13- Kyriazanos ID, Sfiniadakis I, Gizaris V, Hountis P, Hatziveis K, Dafnopoulou A, Datsakis K. The incidence of *Helicobacter pylori* infection is not increased among obese young individuals in Greece. *J Clin Gastroenterol* 2002; 34:541-546.
 - 14- Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* 2003;52:637-40.
 - 15- Talley, N. J., D. G. Newell, J. E. Ormand, H. A. Carpenter, W. R. Wilson, A. R. Zinsmeister, G. I. Perez-Perez, and M. J. Blaser. 1991. Serodiagnosis of *Helicobacter pylori*: comparison of enzyme-linked immunosorbent assays. *J. Clin. Microbiol.* 29:1635-1639.
 - 16- B. A. M. van de Wouw, W. A. de Boer, A. R. Jansz, R. T. J. M. Roymans, and A. P. G. Staals. 1996. Comparison of three commercially available enzymelinked immunosorbent assays and biopsy-dependent diagnosis for detecting *Helicobacter pylori* infection. *J. Clin. Microbiol.* 34:94-97.
 - 17- Cho I, Blaser MJ, Francois F, et al. *Helicobacter pylori* and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* 2005;162:579-584.
 - 18- Isomoto H, Nakazato M, Ueno H, et al. Low plasma ghrelin levels in patients with *Helicobacter pylori*-associated gastritis. *Am J Med* 2004;117:429-432.
 - 19- Nwokolo CU, Freshwater DA, O'Hare P, Randeve HS. Plasma ghrelin following cure of *Helicobacter pylori*. *Gut* 2003;52:637-640.
 - 20- Bardhan, P. K. 1997. Epidemiological features of *Helicobacter pylori* in developing countries. *Clin. Infect. Dis.* 25:973-978.
 - 21- Hussein NR, Robinson K, Atherton JC. A study of Age-Specific *Helicobacter pylori* Seropositivity Rates in Iraq. *Helicobacter.* 2008 Aug 1;13(4):306-7.
 - 22- Cho I, Blaser MJ, Francois F, et al. *Helicobacter pylori* and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol* 2005;162:579-84.
 - 23- Carabotti M, D'Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. *Helicobacter pylori* infection in obesity and its clinical outcome after bariatric surgery. *World J Gastroenterol* 2014;20:647-653.
 - 24- Nweneka CV, Prentice AM. *Helicobacter pylori* infection and circulating ghrelin levels: a systematic review. *BMC Gastroenterol.* 2011;11:7.
 - 25- Azuma T, Suto H, Ito Y, et al. Gastric leptin and *Helicobacter pylori* infection. *Gut* 2001;49:324-9.